Acute phase reactants and suppressive E-receptor factor in various groups of patients receiving autolymphocyte therapy.
The levels of selected acute phase proteins (APP) and of tumor-associated suppressive E-receptor factor (SER) were determined in sequential serum specimens from (1) cancer patients under treatment with autolymphocyte therapy (ALT) or plasmapheresis, (2) patients with acute infections, (3) patients with autoimmune disorders, and (4) other nonmalignant diseases. The absolute serum levels of APP, including SER, and their patterns of change over time are shown to differ significantly between cancer and non-cancer patients. The absolute levels of APP and the patterns of change over time appear to be useful indicators of immune status and predictors of antitumor response to autolymphocyte (and possibly other anti-cancer) therapy.
Knee
T S
TS
Department of Microbiology, Boston University School of Medicine, MA 02118.
Osband
M S
MS
Carpinito
G A
GA
Seder
R E
RE
Nordin
A
A
Oh
S K
SK
D000209:Acute-Phase Proteins / Q000032:analysis*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001327:Autoimmune Diseases / Q000097:blood; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000628:therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood*; D007167:Immunotherapy; D007239:Infections / Q000097:blood; D007680:Kidney Neoplasms / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000628:therapy; D010956:Plasmapheresis; D012016:Reference Values; D012709:Serum Albumin / Q000378:metabolism
D000209:Acute-Phase Proteins; D007166:Immunosuppressive Agents; D012709:Serum Albumin